NMC
GALT icon

Nine Masts Capital’s Galectin Therapeutics GALT Stock Holding History

Nine Masts Capital’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,324
Closed -$53.9K – 220
2026
Q1 		$53.9K Buy
+19,324
New +$58.8K 0.01% 135

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Nine Masts Capital's GALT Position: Q2 2026 in Review

Nine Masts Capital sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 19,324 shares — an estimated $53.9K sold.

Nine Masts Capital first reported a position in GALT in Q1 2026 and held it in 1 quarter. The position peaked at $53.9K in Q1 2026. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Nine Masts Capital reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Nine Masts Capital sold 19,324 Galectin Therapeutics shares in Q2 2026, an estimated $53.9K.
  • Nine Masts Capital first reported a position in Galectin Therapeutics in Q1 2026 and held it in 1 quarter.
  • Nine Masts Capital's Galectin Therapeutics position peaked at $53.9K in Q1 2026.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.